Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence.
Journal Title: Annals of Hepatology - Year 2010, Vol 9, Issue 2
Abstract
Background. Patients who receive liver transplantation for chronic hepatitis B infection require long-term combination therapy with hepatitis B immunoglobulin (HBIG) and oral antiviral medication to prophylax against graft re-infection. This study examines the efficacy and patient preference of subcutaneous (SC) administration of HBIG in maintaining anti HBs titres > 100 IU/L. Materials and methods. 12 patients who were stable while receiving our standard IM HBIG protocol received an alternate formulation by SC injection, consisting of 10 mL (3120 IU) HBIG as 4 x 2.5 mL SC injections. SC injection were repeated as soon as titres reached 100-150 IU/mL during the 3 month study period. A questionnaire was administered upon study entry and exit to subjectively assess patient preference. Results. Anti- HBs Cmax after first injection was 441.6 IU/L ± 81.5, and Tmax was 7.1 ± 3.2 days. SC injections were required every 56 days, which compared well to the frequency of required IM injections prior to study enrollment of 45 days. The patients mean ratings of pain on a 0-10 scale were 5 for the IM route and 1.6 for the SC route. All patients preferred the SC injections to the IM. Conclusion. SC administration of HBIG can effectively maintain anti HBs levels above the requisite 100 IU/L while substantially decreasing patient discomfort and improving patient satisfaction, and therefore becomes a very attractive alternative to IM HBIG injections. Further studies and wider use of SC HBIG based on this study may alter the standard practice of transplantation centers
Authors and Affiliations
Janakie Singham, Erica Greanya, Kirby Lau, Siegfried Erb, Nilu Partovi, Eric Yoshida
Pegylated interferon, but not conventional interferon therapy induced severe skin lesions
Probiotics: a possible role in treatment of adult and pediatric non alcoholic fatty liver disease
Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery
Background: Obesity is the most frequent risk factor associated with NAFLD, and bariatric surgery (BAS) is traditionally indicated for the treatment of severely obese individuals. Here, we discuss the behavior and progno...
Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study
Cell-based therapy to reverse advanced alcoholic liver fibrosis